

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound comprising a bifunctional fusion glycoprotein or bifunctional glycoprotein conjugate, the compound comprising a carbohydrate complement, and:
 - a. at least one first portion which possesses enzymatic activity;
 - b. at least one second portion which binds specifically to an epitope of a tumor-specific antigen wherein said second portion is not an antibody or antibody fragment; wherein the carbohydrate complement comprises at least one exposed terminal carbohydrate residue selected from the group consisting of mannose, galactose, N-acetylglucosamine, N-acetylactose, glucose and fucose.
2. (Currently amended) ~~A~~ The compound as claimed in claim 1, wherein the exposed carbohydrate residue is produced by enzymatic degradation.
3. (Currently amended) ~~A~~ The compound ~~as claimed according to~~ in claim 2, wherein the enzymatic degradation is effected by an enzyme selected from the group consisting of endoglycosidases, exoglycosidases, and neuraminidases, and a combination thereof.
4. (Currently amended) ~~A~~ The compound ~~as claimed in~~ according to claim 1, wherein the exposed carbohydrate residue is produced by chemical degradation.
5. (Currently amended) ~~A~~ The compound ~~as claimed in~~ according to claim 1 wherein the exposed carbohydrate residue is added to the compound by chemical means.
6. (Currently amended) ~~A~~ The compound ~~as claimed in~~ according to claim 1, wherein the first portion consists essentially of an enzyme.

7. (Currently amended) A The compound as claimed in according to claim 6, wherein the enzyme is selected from the group consisting of penicillin G amidase, penicillin V amidase, .beta.-lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, .beta.-glucosidase, and .beta.-glucuronidase.

8. (Canceled)

9. (Currently amended) A compound as claimed in claim 1, wherein the tumor cell marker to which the second portions binds comprises a tumor associated antigen selected from the group consisting of CEA, N-CAM, N-cadherin, PEM, GICA, TAG-72, TF.beta., GM3, GD3, GM2, GD2, GT3, HMWMAA, pMel17, gp113 (Muc18), p53, p97, MAGE-1, gp105, erbB2, EGF-R, PSA, transferrin-R, P-glycoprotein and cytokeratin.

10- 11 (Canceled)

12. (Currently amended) A The compound as claimed in according to claim 1, wherein the first portion and the second portion are connected by a linker molecule.

13. (Canceled)

14. (Currently amended) A The compound as claimed in according to claim 1, comprising a fusion glycoprotein that has been synthesized in CHO cells, the cells having been selected for a high level of expression of the glycoprotein.

15. (Currently amended) A The compound as claimed in according to claim 1, wherein the exposed carbohydrate is a galactose or a mannose.

16. (Currently amended) A pharmaceutical preparation containing a the compound as claimed in according to claim 1 in a pharmaceutically acceptable vehicle.

17. (Currently amended) A pharmaceutical preparation containing a the compound ~~as claimed in~~ according to claim 1, and an agent capable of lowering the pH in a tumor to be treated, in a pharmaceutically acceptable vehicle.

18. (Currently amended) A pharmaceutical preparation, containing a the compound ~~as claimed in~~ according to claim 1, and galactose, in a pharmaceutically acceptable vehicle.

19-21 (Canceled)